Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. by Mead, Gillian E et al.
Selective serotonin reuptake inhibitors (SSRIs) for stroke
(Protocol)
Mead GE, Hankey GJ, Kutlubaev MA, Lee R, Bailey M, Hackett ML
This is a reprint of a Cochrane protocol, prepared and maintained by The Cochrane Collaboration and published in The Cochrane
Library 2011, Issue 11
http://www.thecochranelibrary.com
Selective serotonin reuptake inhibitors (SSRIs) for stroke (Protocol)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
3METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8HISTORY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iSelective serotonin reuptake inhibitors (SSRIs) for stroke (Protocol)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Protocol]
Selective serotonin reuptake inhibitors (SSRIs) for stroke
Gillian E Mead1, Graeme J Hankey2, Mansur A Kutlubaev3 , Rebecca Lee4, Matthew Bailey5, Maree L Hackett6
1Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK. 2Department of Neurology, Royal PerthHospital, Perth,
Australia. 3Division of Clinical Neurosciences, Western General Hospital, Edinburgh, UK. 4Department of Medicine of the Elderly,
Western General Hospital, Edinburgh, UK. 5Department of Medicine of the Elderly, Liberton Hospital, Edinburgh, UK. 6Department
of Neurological and Mental Health, The George Institute for International Health, Sydney, Australia
Contact address: Gillian E Mead, Centre for Clinical Brain Sciences, University of Edinburgh, Room S1642, Royal Infirmary, Little
France Crescent, Edinburgh, EH16 4SA, UK. gillian.e.mead@ed.ac.uk. gmead@staffmail.ed.ac.uk.
Editorial group: Cochrane Stroke Group.
Publication status and date: New, published in Issue 11, 2011.
Citation: Mead GE, Hankey GJ, Kutlubaev MA, Lee R, Bailey M, Hackett ML. Selective serotonin reuptake inhibitors (SSRIs) for
stroke. Cochrane Database of Systematic Reviews 2011, Issue 11. Art. No.: CD009286. DOI: 10.1002/14651858.CD009286.
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
Our objective is to determine whether SSRIs improve recovery after stroke.
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B A C K G R O U N D
Description of the condition
Stroke is defined as a sudden onset focal neurological disturbance,
assumed to be vascular in origin, and lasting more than 24 hours
(Hatano 1976). Each year, it affects about 16 million people for
the first time and causes about 5.7 million deaths (Strong 2007).
Moreover, survivors of stroke account for about 51million disabil-
ity-adjusted life years (DALYs). This is because recovery of func-
tional independence after stroke only occurs in about half of all
survivors of stroke, and mainly during the first six months after a
stroke (Hankey 2007a; Hankey 2007b). Althoughmajor advances
in the early reperfusion of ischaemic stroke have been realised in
recent years, for example by intravenous thrombolysis and preven-
tion of early recurrent stroke, effective, safe and widely accessible
and affordable treatments that facilitate early and sustained recov-
ery after stroke are urgently needed to further reduce the burdens
of disability and dependency after stroke.
Description of the intervention
Selective serotonin reuptake inhibitors (SSRIs) are a class of drug
that have been available for many years. Their main use in clinical
practice is for mood disorders, particularly depression. They are
sometimes used in stroke tomanage emotionalism (Hackett 2010)
(that is emotional behaviour that the patient reports as being out-
side normal control and which occurs in situations that previously
would not have provoked such behaviour). Recently, SSRIs have
been described in small studies as possibly having a favourable ef-
fect on motor recovery after stroke (Yi 2010; Chollet 2011). The
recently published ’Fluoxetine on Motor Rehabilitation after Is-
chemic Stroke’ (FLAME) trial reported that 15 (26%) of 56 acute
stroke patients allocated to receive fluoxetine and 5 (9%) of 54
allocated to placebo had a modified Rankin score (mRS) of 0 to
2 (no dependency on other people) at three months, odds ratio
(OR) of 3.8 (95% confidence interval (CI) 1.2 to 10.7) (Chollet
2011).
How the intervention might work
In animals, SSRIs have several potentially beneficial effects on
both normal and diseased brain. First, SSRIs have a neurotrophic
effect. Neurotrophins are a family of proteins that are involved
in embryogenesis (formulation of an embryo) and organogenesis
(development of organs). They control neural plasticity (ability to
change, or easily changed or shaped) in adults, regulate synaptic
activity and neurotransmitter synthesis and are essential for the re-
generation of nerves (Lang 2004). Adult neurogenesis is generally
restricted to specific areas of the brain, namely the subependymal
cells of the ventricular system and the subgranular zone of the
dentate gyrus in the hippocampus (Ming 2005). SSRIs increase
neurogenesis and expression of neurotrophic or growth factors in
the adult hippocampus (Schmidt 2007) and this is likely to ac-
count for the behavioural benefits of antidepressants in animals
(Santarelli 2003). Importantly, several studies have shown that
migration of new neurones to damaged areas of brain may occur
(Wiltrout 2007) and that neurogenesis can also occur within ar-
eas of damaged brain in patients with ischaemic stroke (Taupin
2006). Secondly, fluoxetine may have a neuroprotective effect as-
sociated with its anti-inflammatory effect (for example repression
of microglia activation) (Lim 2009) and enhancement of specific
protein expression (hypoxia inducible factor-1 alpha, hemeoxy-
genaste-1) (Shin 2009). Thirdly, SSRIs can indirectly affect the
adrenergic system through upregulation (that is increase a cellular
component of a cell, such as ribonucleic acid (RNA) or protein,
in response to an external variable) of beta1 receptors (Palvimaki
1994). In healthy humans, functionalmagnetic resonance imaging
studies have demonstrated that fluoxetine can modulate cerebral
motor activity (Loubinoux 1999). In eight patients with pure mo-
tor stroke given fluoxetine, there was hyperactivation in the ipsi-
lesional (that is on the same side as the stroke lesion) primary mo-
tor cortex during a motor task; moreover, fluoxetine significantly
improved motor skills of the affected side (Pariente 2001). Zittel
et al investigated the effects of a single dose of 40 mg citalopram in
eight chronic stroke patients; dexterity was significantly improved
(Zittel 2008).
Why it is important to do this review
It is rare for treatments for neurological diseases such as stroke to
have a dramatically favourable effect, such as that of fluoxetine
on recovery after stroke as suggested by the FLAME trial (Chollet
2011). Treatments for stroke are far more likely to have a mod-
est treatment effect, at best, which can nevertheless be clinically
worthwhile. If modest but worthwhile treatment effects are to be
reliably detected or refuted, then any errors in the evaluation of
their effectiveness need to be much smaller than the effect of the
treatment itself, otherwise the errors may nullify the effect of the
treatment and lead to a false negative result. Similarly, if the treat-
ment is not effective, substantial errors could lead to a false positive
result, or an exaggerated positive result.
The common sources of error in studies of interventions are sys-
tematic error (bias) and random error. Systematic errors can be
minimised by proper randomisation, analysis by allocated treat-
ment, evaluation of outcome evaluation blinded to the allocated
treatment, emphasis on the overall primary results, and publica-
tion of all studies irrespective of the results; whereas random error
can really only beminimised by studying the effect of the treatment
compared with a control on a large number of major outcomes,
and therefore in all studies. It is therefore important to systemat-
ically review all the relevant studies that have evaluated the effect
of SSRIs on recovery after stroke (published and unpublished) to
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minimise systematic and random error in our estimates of the po-
tential effects of SSRIs on recovery after stroke. Although a review
of fluoxetine in stroke has already been undertaken and published
(Yi 2010), the searches were done in 2009 and so the review did
not include the FLAME trial (Chollet 2011); and the review was
limited to fluoxetine rather than all SSRIs (Yi 2010). Furthermore,
although the authors of the existing review considered some im-
portant aspects of study quality, the Cochrane risk of bias tools
were not used so the reviewers may have missed some sources of
bias. Thus, there is a need to produce an updated, methodologi-
cally robust systematic review incorporating all the relevant trials
that have examined the role of all SSRIs for stroke recovery.
If a simple, inexpensive drug such as one of the SSRIs is shown
to improve stroke recovery, this would have major implications
for patients, carers, health services, social care services and the
economy.
O B J E C T I V E S
Our objective is to determine whether SSRIs improve recovery
after stroke.
M E T H O D S
Criteria for considering studies for this review
Types of studies
The review will be restricted to all relevant randomised controlled
trials (RCTs) in patients with a clinical diagnosis of stroke (Hatano
1976) where an SSRI has been given within the first three months
of stroke onset. We will exclude trials using a cross-over design,
or where two or more of the interventions were compared against
each other rather than a placebo or standard care group. We will
include identified trials in all languages. There will be no restric-
tion on the eligibility of RCTs on the basis of sample size or dura-
tion of follow-up.We will consider unpublished reports, abstracts,
brief and preliminary reports for inclusion on the same basis as
published reports. If we find studies meeting all the criteria for
inclusion but not presenting any outcome data, and if such data
are not available from the authors, the studies cannot be used to
contribute data to any pooled estimate of effect. We will list these
studies in an additional table.
Types of participants
Wewill include any person who has had a stroke (Hatano 1976) in
the previous three months. We will include those with subarach-
noid haemorrhage.Wewill exclude trials that includedmixed pop-
ulations (such as stroke and head injury or other central nervous
system disorders) unless separate results for patients with stroke
are available.
Types of interventions
We will include any drug classified as a SSRI (for example fluvox-
amine, fluoxetine, sertraline, citalopram and paroxetine). We will
include any dose or mode of delivery, given for any duration and
for any reason, for example to aid neurological recovery, to treat
depression or anxiety or emotionalism, or to prevent depression or
anxiety or other mood disorders. We will not include drugs that
have mixed effects that include SSRI actions.
Types of outcome measures
Primary outcomes
Disability (measured, for example, by the Barthel Index, Func-
tional Independence Measure) and dependence (measured by the
modified Rankin score, for example).
Secondary outcomes
Impairments, depression, anxiety, quality of life, fatigue, health-
care cost, death, adverse events, leaving the trial early.
Search methods for identification of studies
See the ’Specialized register’ section in the Cochrane Stroke Group
module.
Electronic searches
We will search the following electronic bibliographic databases:
• Cochrane Stroke Group Trials Register;
• Cochrane Depression Anxiety and Neurosis Group Trials
Register;
• Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library, latest issue);
• MEDLINE (from 1948) (Appendix 1);
• EMBASE (from 1980);
• CINAHL (from 1982);
• AMED (Allied and Complementary Medicine) (from
1985);
• PsycINFO (from 1967);
• PsycBITE Pyschological Database for Brain Impairment
Treatment Efficacy (www.psycbite.com/).
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We developed the MEDLINE search strategy with the help of the
Cochrane Stroke Group Trials Search Co-ordinator and will adapt
it for the other databases. We will search for relevant trials in all
languages and arrange for translation of trial reports published in
languages other than English.
Searching other resources
In an effort to identify further published, unpublished and ongo-
ing trials, we will:
1. search the online Clinical Trial Results and Clinical Trial
Registries for Bristol-Myers Squibb, Eli Lilly, Forest,
GlaxoSmithKline, Novartis, Organon, Pfizer, Roche, and Wyeth;
2. search the following ongoing trials registers:
i) Stroke Trials Registry (www.strokecenter.org/trials),
ii) ClinicalTrials.gov (www.ClinicalTrials.gov),
iii) ClinicalStudyResults.org (
www.Clinicalstudyresults.org),
iv) Current Controlled Trials (http://www.controlled-
trials.com),
v) EU Clinical Trials Register (https://
www.clinicaltrialsregister.eu);
3. search reference lists of included studies and relevant
reviews;
4. use Science Citation Index Cited Reference Search for
forward tracking of important references (i.e. of included trials
and reviews);
5. contact authors and researchers in the field.
We will search for relevant trials in all languages and arrange for
translation of trial reports published in languages other than En-
glish.
Data collection and analysis
Selection of studies
One review author (GM, MH, MK, MB or RL) will perform the
electronic searches, read titles and available abstracts and exclude
obviously irrelevant studies. We will obtain the full text of all
remaining studies. One experienced review author (GMorMHor
GH) and one less experienced review author (MK, RL orMB) will
independently scrutinise each full text article and decide whether
they fulfil study inclusion criteria. Should any disagreements arise,
we will ask a third review author for an opinion and a consensus
will be reached.
We will include a study flow diagram which will include the num-
ber of unique references identified by the searches, the number of
records excluded after preliminary screening of titles and abstracts,
and the number of records retrieved in full text. We will take ap-
propriate notes during the search process to ensure that the flow
diagram can be completed correctly.
Data extraction and management
We will develop a paper data extraction form based on the one
used for previousCochrane reviews in depression. It will be piloted
on three papers and modified as appropriate. Two review authors
(an experienced and a less experienced one) will independently
extract data from each study. Any disagreements will be resolved
by discussion.
We will extract data on the following:
1. the report: author, year and source of publication;
2. the study: sample characteristics, social demography;
3. the participants: stroke sequence (first ever versus
recurrent), social situation, time since stroke onset, prior history
of psychiatric illness, current neurological status, stroke severity,
whether people with aphasia were recruited, the proportion with
depression at baseline (if recorded by trialists). We will not extract
information on location or size of lesion as this is unlikely to have
been recorded by the trialists, and brain imaging often does not
show a visible lesion, particularly for patients with minor strokes;
4. the research design and features: adherence, non-response
and length of follow-up;
5. the intervention: type, duration, dose, timing and mode of
delivery;
6. the effect size: sample size, nature of outcome, estimate and
standard error.
We will store the data electronically. We will obtain missing infor-
mation from the primary investigators, if possible.
Assessment of risk of bias in included studies
We will assess risk of bias using The Cochrane Collaboration’s risk
of bias tables. For each study, we will determine whether there was
allocation concealment; how randomisation was performed (in-
cluding how sequences were generated); whether there was blind-
ing of patient, personnel and outcome assessors; whether there
were incomplete outcome data and whether there was selective
outcome data reporting.
We will also record whether there was an imbalance in baseline
characteristics, whether there was minimisation or stratification
based on baseline variables, and early stopping of the intervention.
Measures of treatment effect
We will carry out statistical analysis using the Review Manager
software, RevMan 5.1 (RevMan 2011). We will calculate a sum-
mary statistic for each outcome measure used to describe the ob-
served treatment effect. All summary statistics reported in this re-
view will refer to effects at either: (1) the end of intervention, or
(2) the end of follow-up.
Unit of analysis issues
We anticipate that most of the trials will have a simple parallel
group design where each individual will be randomised to one of
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two treatment groups. However, there may be trials where each
individual can be randomised to one of three (or more) possible
groups, including different doses of SSRIs. We will deal with this
by performing subgroup analyses to explore the influence of the
dose of a drug on the outcome.
Dealing with missing data
We will approach primary investigators for missing data. When
missing data are not available, we will perform sensitivity analyses
to determine the influence of including trials with missing data.
Assessment of heterogeneity
Wewill investigate statistical heterogeneity by theChi2 test and the
I2 statistic, available in RevMan. If there is evidence of statistical
heterogeneity (I2 > 50%), we will use a random-effects model and
perform subgroup and sensitivity analyses as appropriate.
Assessment of reporting biases
Wewill assess publication bias by a funnel plot.Wewill try to avoid
language bias by including all studies, irrespective of language, and
seek translationwhere needed.Wewill check for selective reporting
of results by scrutinising the aims and methods of the trials and
comparing these with outcomes reported. Should we find similar
papers by the same authors, we will contact the authors to ensure
that the publications are not duplicates.
Data synthesis
For dichotomous data, we will report risk ratios (RR). For ordinal
scales, where there is a well-recognised cut-point in the scale (for
example modified Rankin) we will analyse the data as a dichoto-
mous outcome (dependent or independent). For ordinal scales
with no recognised cut-point, we will analyse the data as continu-
ous data. The data required for meta-analyses of continuous data
in RevMan are means and standard deviations (SD). When ex-
tracting continuous data from the study reports we will take pre-
cautions by checking whether standard error (SE) was mistakenly
reported as SD. We will use SE or 95% CI to compute SD when
SDs are missing.
For ordinal scales and continuous data, we will calculate standard-
ised mean differences (SMD) because we expect different scales
to be used for the same outcomes (for example Barthel Index
and Functional Independence Measure for disability). It should
be noted that the SMD does not correct for differences in the
direction of the scale. If some scales increase with disease severity
and others decrease, we will multiply the mean value from one
set of studies by -1. An example of this is the National Institute
of Health Stroke Scale (where a low score represents a less severe
stroke) and the Scandinavian Stroke Scale (where a low score in-
dicates a more severe stroke).
Subgroup analysis and investigation of heterogeneity
We will perform the following subgroup analyses: depression ver-
sus no depression at entry, motor versus non-motor deficits, dose
of drug, type of SSRI, brand of drug.
Sensitivity analysis
We will perform sensitivity analyses to explore the influence of
the key aspects of trial quality that we identified during our as-
sessment of risk of bias. For example, if some trials do not include
blinded outcome assessment (perhaps relying instead on self-re-
port), we will exclude these trials from the analyses in order to
explore whether this makes any different to effect sizes.
A C K N OW L E D G E M E N T S
We are grateful to Brenda Thomas for her assistance in devising
the search strategy, and to the editorial and peer reviewers Peter
Langhorne, Brenda Thomas, Ashma Krishnan and Robert Robin-
son.
R E F E R E N C E S
Additional references
Chollet 2011
Chollet F, Tardy J, Albucher J-F, Thalamas C, Berard
E, Lamy C, et al.Fluoxetine for motor recovery after
acute ischaemic stroke (FLAME): a randomised placebo-
controlled trial. Lancet Neurology 2011;10:123–30.
Hackett 2010
Hackett ML, Yang M, Anderson CS, Horrocks JA, House
A. Pharmaceutical interventions for emotionalism after
stroke. Cochrane Database of Systematic Reviews 2010, Issue
2. [DOI: 10.1002/14651858.CD003690.pub3]
Hankey 2007a
Hankey GJ, Spiesser J, Hakimi Z, Bego G, Carita P, Gabriel
S. Rate, degree and predictors of recovery from disability
following ischemic stroke. Neurology 2007;68:1583–7.
Hankey 2007b
Hankey GJ, Spiesser J, Hakimi Z, Carita P, Gabriel S. Time
frame and predictors of recovery from disability following
recurrent ischemic stroke. Neurology 2007;68:202–5.
5Selective serotonin reuptake inhibitors (SSRIs) for stroke (Protocol)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Hatano 1976
Hatano S. Experience from a multicentre stroke register:
a preliminary report. Bulletin of the World Health
Organization 1976;54:541–53.
Lang 2004
Lang UE, Jockers-Scherubl MC, Hellweg R. State of the art
of the neurotrophin hypothesis in psychiatric disorders:
implications and limitations. Journal of Neural Transmission
2004;111:387–411.
Lim 2009
Lim C-M, Kim W-W, Park J-Y, Kim C, Yoon SH, Lee
J-K. Fluoxetine affords robust neuroprotection in the
postischemic brain via its anti-inflammatory effect. Journal
of Neuroscience Research 2009;87:1037-45.
Loubinoux 1999
Loubinoux I, Boulanouar K, Ranjeva J-F, Carel C, Berry
I, Rascol O, et al.Cerebral functional magnetic resonance
imaging activation modulated by a single does of the
monoamine neurotransmission enhancers fluoxetine and
fenozolone during hand sensorimotor tasks. Journal of
Cerebral Blood Flow and Metabolism 1999;19:1365–75.
Ming 2005
Ming GL, Song H. Adult neurogenesis in the mammalian
central nervous system. Annual Review of Neuroscience
2005;28:223–50.
Palvimaki 1994
Palvimaki E-P, Laakso A, Kuoppamaki M, Syvilahti E,
Hietala J. Up-regulation of beta l-adrenergic receptors in rat
brain after chronic citalopram and fluoxetine treatments.
Psychopharmacology 1994;115:543–6.
Pariente 2001
Pariente J, Loubinoux I, Carel C, Albucher J-F, Leger A,
Manelfe C, et al.Fluoxetine modulates motor performance
and cerebral activation of patients recovering from stroke.
Annals of Neurology 2001;50:718-29.
RevMan 2011
The Nordic Cochrane Centre, The Cochrane Collaboration.
Review Manager (RevMan). 5.1. Copenhagen: The Nordic
Cochrane Centre, The Cochrane Collaboration, 2011.
Santarelli 2003
Santarelli L, Saxe M, Gross C, Surget A, Battaglia F,
Dulawa S, et al.Requirement of hippocampal neurogenesis
antidepressant treatments and animal models of depressive-
like behaviour. Behavioural Pharmacology 2003;301:805–9.
Schmidt 2007
Schmidt HD, Duman RS. The role of neurotrophic
factors in adult hippocampal neurogenesis, antidepressant
treatments and animal models of depressive-like behaviour.
Behavioural Pharmacology 2007;18:391–418.
Shin 2009
Shin TK, Kang MS, Lee HY, Seo MS, Kim SG, Kim
CD, et al.Fluoxetine and sertraline attenuate postischemic
brain injury in mice. Korean Journal of Physiology and
Pharmacology 2009;13:257–63.
Strong 2007
Strong K, Mathers C, Bonita R. Preventing stroke: saving
lives around the world. Lancet Neurology 2007;6:182–7.
Taupin 2006
Taupin P. Adult neurogenesis and neuroplasticity. Restorative
Neurology and Neuroscience 2006;24:9–15.
Wiltrout 2007
Wiltrout C, Lang B, Yan Y, Dempsey RJ, Vemuganti R.
Repairing brain after stroke: a review on post-ischaemic
neurogenesis. Neurochemistry International 2007;50:
1028–41.
Yi 2010
Yi ZM, Liu F, Zhai SD. Fluoxetine for the prophylaxis
of post-stroke depression in patients with stroke: a meta-
analysis. International Journal of Clinical Practice 2010;64:
1310–7.
Zittel 2008
Zittel S, Weiller C, Liepert J. Citalopram improves dexterity
in chronic stroke patients. Neurorehabilitation and Neural
Repair 2008;22:311–4.
∗ Indicates the major publication for the study
6Selective serotonin reuptake inhibitors (SSRIs) for stroke (Protocol)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A P P E N D I C E S
Appendix 1. Medline search strategy
MEDLINE (Ovid)
1. cerebrovascular disorders/ or exp basal ganglia cerebrovascular disease/ or exp brain ischemia/ or exp carotid artery diseases/ or exp
intracranial arterial diseases/ or exp “intracranial embolism and thrombosis”/ or exp intracranial hemorrhages/ or stroke/ or exp brain
infarction/ or vertebral artery dissection/
2. (stroke or poststroke or post-stroke or cerebrovasc$ or brain vasc$ or cerebral vasc$ or cva$ or apoplex$ or SAH).tw.
3. ((brain$ or cerebr$ or cerebell$ or intracran$ or intracerebral) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$)).tw.
4. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracranial or subarachnoid) adj5 (haemorrhage$ or hemorrhage$ or haematoma$
or hematoma$ or bleed$)).tw.
5. hemiplegia/ or exp paresis/
6. (hemipleg$ or hemipar$ or paresis or paretic).tw.
7. exp Gait Disorders, Neurologic/
8. or/1-7
9. exp Serotonin Uptake Inhibitors/
10. ((serotonin or 5-HT or 5 HT or 5-hydroxytryptamine or 5 hydroxytryptamine) adj5 (uptake or reuptake or re-uptake) adj5
inhib$).tw.
11. SSRI$1.tw.
12. (alaproclat$ or cericlamin$ or citalopram or dapoxetin$ or escitalopram or femoxetin$ or fluoxetin$ or fluvoxamin$ or paroxetin$
or sertralin$ or trazodone or vilazodone or zimelidine).tw.
13. (alaproclat$ or cericlamin$ or citalopram or dapoxetin$ or escitalopram or femoxetin$ or fluoxetin$ or fluvoxamin$ or paroxetin$
or sertralin$ or trazodone or vilazodone or zimelidine).nm.
14. 9 or 10 or 11 or 12 or 13
15. 8 and 14
16. exp animals/ not humans.sh.
17. 15 not 16
18. Randomized Controlled Trials as Topic/
19. random allocation/
20. Controlled Clinical Trials as Topic/
21. control groups/
22. clinical trials as topic/ or clinical trials, phase i as topic/ or clinical trials, phase ii as topic/ or clinical trials, phase iii as topic/ or
clinical trials, phase iv as topic/
23. Clinical Trials Data Monitoring Committees/
24. double-blind method/
25. single-blind method/
26. Placebos/
27. placebo effect/
28. cross-over studies/
29. Multicenter Studies as Topic/
30. Therapies, Investigational/
31. Drug Evaluation/
32. Research Design/
33. Program Evaluation/
34. evaluation studies as topic/
35. randomized controlled trial.pt.
36. controlled clinical trial.pt.
37. (clinical trial or clinical trial phase i or clinical trial phase ii or clinical trial phase iii or clinical trial phase iv).pt.
38. multicenter study.pt.
39. (evaluation studies or comparative study).pt.
40. meta analysis.pt.
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41. meta-analysis as topic/
42. random$.tw.
43. (controlled adj5 (trial$ or stud$)).tw.
44. (clinical$ adj5 trial$).tw.
45. ((control or treatment or experiment$ or intervention) adj5 (group$ or subject$ or patient$)).tw.
46. (quasi-random$ or quasi random$ or pseudo-random$ or pseudo random$).tw.
47. ((multicenter or multicentre or therapeutic) adj5 (trial$ or stud$)).tw.
48. ((control or experiment$ or conservative) adj5 (treatment or therapy or procedure or manage$)).tw.
49. ((singl$ or doubl$ or tripl$ or trebl$) adj5 (blind$ or mask$)).tw.
50. (coin adj5 (flip or flipped or toss$)).tw.
51. latin square.tw.
52. versus.tw.
53. (cross-over or cross over or crossover).tw.
54. placebo$.tw.
55. sham.tw.
56. (assign$ or alternate or allocat$ or counterbalance$ or multiple baseline).tw.
57. controls.tw.
58. (treatment$ adj6 order).tw.
59. (meta-analy$ or metaanaly$ or meta analy$ or systematic review or systematic overview).tw.
60. or/18-59
61. 17 and 60
H I S T O R Y
Protocol first published: Issue 11, 2011
C O N T R I B U T I O N S O F A U T H O R S
Dr Mead, Dr Hackett and Professor Hankey wrote the protocol. All authors read the protocol and approved it. All authors will
contribute to the searches, selection of studies and data extraction. Dr Mead and Dr Hackett will perform the analyses. All authors will
contribute to writing the review.
D E C L A R A T I O N S O F I N T E R E S T
Maree Hackett and Graeme Hankey are co-principal investigators on a study designed to access the impact of fluoxetine on disability
and dependency after stroke. It is envisaged that the results of this trial would be eligible for inclusion in this review.
S O U R C E S O F S U P P O R T
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Internal sources
• None, Not specified.
External sources
• None, Not specified.
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